肺移植候选慢阻肺患者的生存:BODE评分再审视
该回顾性分析比较UNOS肺移植候选者中慢阻肺患者(n=4,377)与BODE评分验证队列(n=625)的生存,发现UNOS队列BODE第四分位中位生存为59个月(95%CI 51-77),验证队列为37个月(95%CI 29-42);控制BODE评分并将肺移植作为竞争终点后,验证队列死亡风险更高(SHR 4.8;95%CI 4.0-5.7;P<.001)。结论:以BODE评分外推预后会高估肺移植候选慢阻肺患者的死亡风险,可能与移植评估筛查导致合并症患病率较低有关。
要点
- BODE评分用于慢阻肺肺移植预后判断尚未在该情境下验证。
- UNOS候选者BODE第四分位中位生存59个月,长于验证队列的37个月。
- 以BODE评分外推预后会高估肺移植候选者的死亡风险。
核心结论
- 以BODE评分外推预后会高估肺移植候选慢阻肺患者的死亡风险,可能因移植评估筛查使合并症患病率较低。
研究设计与样本
- 回顾性分析UNOS肺移植候选者中慢阻肺患者(n=4,377)的生存,与BODE评分验证队列(n=625)比较。
- 控制BODE评分并将肺移植作为竞争终点建模。
主要发现
- UNOS队列BODE第四分位中位生存59个月(95%CI 51-77),BODE验证队列为37个月(95%CI 29-42)。
- 控制BODE评分并以肺移植为竞争终点时,验证队列死亡风险更高(SHR 4.8;95%CI 4.0-5.7;P<.001)。
- BODE第四分位风险差异最大(SHR 6.1;95%CI 4.9-7.6;P<.001)。
临床怎么用
- 评估慢阻肺肺移植候选者预后时,不宜直接套用BODE评分在一般慢阻肺人群中的死亡率外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The BMI, obstruction, dyspnea, and exercise capacity (BODE) score is used to inform prognostic considerations for lung transplantation for COPD, but it has not been validated in this context. A large proportion of mortality in COPD is attributable to comorbidities that could preclude transplant candidacy. We hypothesized that patients with COPD who are selected as transplant candidates experience better survival than traditional interpretation of BODE scores might indicate. METHODS: We performed a retrospective analysis of survival according to the BODE score for patients with COPD in the United Network of Organ Sharing (UNOS) database of lung transplantation candidates (n = 4,377) compared with the cohort of patients with COPD in which the BODE score was validated (n = 625). RESULTS: Median survival in the fourth quartile of BODE score was 59 months (95% CI, 51-77 months) in the UNOS cohort and 37 months (95% CI, 29-42 months) in the BODE validation cohort. In models controlling for BODE score and incorporating lung transplantation as a competing end point, the risk of death was higher in the BODE validation cohort (subhazard ratio, 4.8; 95% CI, 4.0-5.7; P < .001). The risk difference was greatest in the fourth quartile of BODE scores (SHR, 6.1; 95% CI, 4.9-7.6; P < .001). CONCLUSIONS: Extrapolation of prognosis based on the BODE score overestimates mortality risk in lung transplantation candidates with COPD. This is likely due to a lower prevalence of comorbid conditions attributable to the lung transplantation evaluation screening process.
引用
- Reed RM, Cabral HJ, Dransfield MT, et al. Survival of Lung Transplant Candidates With COPD: BODE Score Reconsidered. Chest. 2017. PMID: 29054348. doi:10.1016/j.chest.2017.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。